{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:26:48Z","timestamp":1792520808352,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jocn.2021.03.047","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T15:51:59Z","timestamp":1618933919000},"page":"226-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson\u2019s disease patients: A randomized controlled study"],"prefix":"10.1016","volume":"88","author":[{"given":"Chumpol","family":"Anamnart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Kitjarak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2021.03.047_b0005","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1034\/j.1600-0404.2003.00135.x","article-title":"Levodopa-induced hyperhomocysteinaemia in Parkinson's disease","volume":"108","author":"Yasui","year":"2003","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"10.1016\/j.jocn.2021.03.047_b0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/mds.20261","article-title":"Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients","volume":"20","author":"Lamberti","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2021.03.047_b0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.parkreldis.2005.01.007","article-title":"Reduced plasma homocysteine levels in levodopa\/entacapone treated Parkinson patients","volume":"11","author":"Valkovic","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jocn.2021.03.047_b0020","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.parkreldis.2008.10.005","article-title":"Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients","volume":"15","author":"Nevrly","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"10.1016\/j.jocn.2021.03.047_b0025","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/mds.22607","article-title":"Homocysteine levels after acute levodopa intake in patients with Parkinson's disease","volume":"24","author":"M\u00fcller","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2021.03.047_b0030","first-page":"2409","article-title":"The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia","volume":"20","author":"Guo","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"10.1016\/j.jocn.2021.03.047_b0035","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jocn.2009.09.034","article-title":"L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease","volume":"17","author":"Isobe","year":"2010","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.jocn.2021.03.047_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050496","article-title":"Elevated homocysteine by levodopa is detrimental to neurogenesis in parkinsonian model","volume":"7","author":"Shin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jocn.2021.03.047_b0045","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.neulet.2016.06.011","article-title":"L-DOPA treatment in MPTP-mouse model of Parkinson's disease potentiates homocysteine accumulation in substantia nigra","volume":"628","author":"Bhattacharjee","year":"2016","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jocn.2021.03.047_b0050","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1053\/euhj.1999.1914","article-title":"Homocysteine and atherothrombosis\u2013mechanisms for injury","volume":"21","author":"Thambyrajah","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jocn.2021.03.047_b0055","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1001\/jama.288.16.2015","article-title":"Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis","volume":"288","year":"2002","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jocn.2021.03.047_b0060","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMoa011613","article-title":"Plasma homocysteine as a risk factor for dementia and Alzheimer's disease","volume":"346","author":"Seshadri","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jocn.2021.03.047_b0065","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/mds.27301","article-title":"Parkinson Study Group-DATATOP Investigators, Vitamin B12 and homocysteine levels predict different outcomes in early Parkinson's disease","volume":"33","author":"Christine","year":"2018","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.jocn.2021.03.047_b0070","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.archger.2013.04.015","article-title":"Clinical significance of homocysteine (hcy) on dementia in Parkinson's disease (PD)","volume":"57","author":"Song","year":"2013","journal-title":"Arch Gerontol Geriatr"},{"issue":"6","key":"10.1016\/j.jocn.2021.03.047_b0075","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/mds.22482","article-title":"Cysteine elevation in levodopa-treated patients with Parkinson's disease","volume":"24","author":"M\u00fcller","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2021.03.047_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.parkreldis.2017.08.005","article-title":"Homocysteine and cognitive function in Parkinson's disease","volume":"44","author":"Licking","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jocn.2021.03.047_b0085","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neulet.2016.11.007","article-title":"Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson's disease: A meta-analysis","volume":"636","author":"Xie","year":"2017","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jocn.2021.03.047_b0090","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archneur.61.6.865","article-title":"Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations","volume":"61","author":"O'Suilleabhain","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jocn.2021.03.047_b0095","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.0022-3042.2001.00676.x","article-title":"Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease","volume":"80","author":"Duan","year":"2002","journal-title":"J Neurochem"},{"key":"10.1016\/j.jocn.2021.03.047_b0100","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/WNR.0b013e3282aaa0b4","article-title":"Homocysteine is toxic for dopaminergic neurons in primary mesencephalic culture","volume":"18","author":"Imamura","year":"2007","journal-title":"NeuroReport"},{"key":"10.1016\/j.jocn.2021.03.047_b0105","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.WNL.0000137886.74175.5A","article-title":"Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy?","volume":"63","author":"Postuma","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2021.03.047_b0110","first-page":"1989","article-title":"L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room","volume":"2016","author":"Paul","year":"1860","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jocn.2021.03.047_b0115","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1212\/01.wnl.0000219815.83681.f7","article-title":"Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study","volume":"66","author":"Postuma","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2021.03.047_b0120","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1468-1331.2009.02894.x","article-title":"Hyperhomocysteinemia recurrence in levodopa-treated Parkinson's disease patients","volume":"17","author":"Belcastro","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2021.03.047_b0125","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.parkreldis.2004.07.008","article-title":"Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications","volume":"11","author":"Zoccolella","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jocn.2021.03.047_b0130","doi-asserted-by":"crossref","first-page":"7563705","DOI":"10.1155\/2016\/7563705","article-title":"Homocysteine levels in Parkinson's disease: Is Entacapone effective?","volume":"2016","author":"Kocer","year":"2016","journal-title":"BioMed Res Int"},{"issue":"2","key":"10.1016\/j.jocn.2021.03.047_b0135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ane.12106","article-title":"Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis","volume":"128","author":"Hu","year":"2013","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jocn.2021.03.047_b0140","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1515\/CCLM.1998.032","article-title":"The increase of plasma homocysteine concentrations with age is partly due to the deterioration of renal function as determined by plasma cystatin C","volume":"36","author":"Norlund","year":"1998","journal-title":"Clin Chem Lab Med"},{"issue":"11","key":"10.1016\/j.jocn.2021.03.047_b0145","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1053\/meta.2002.35587","article-title":"Plasma homocysteine and malondialdehyde are correlated in an age- and gender-specific manner","volume":"51","author":"Powers","year":"2002","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.jocn.2021.03.047_b0150","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2143\/AC.61.1.2005138","article-title":"Plasma total homocysteine levels in a healthy Turkish population sample","volume":"61","author":"Taskin","year":"2006","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.jocn.2021.03.047_b0155","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1161\/CIRCULATIONAHA.114.013311","article-title":"Homocysteine and MTHFR mutations","volume":"132","author":"Moll","year":"2015","journal-title":"Circulation"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821001764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821001764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:27:18Z","timestamp":1760822838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586821001764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":31,"alternative-id":["S0967586821001764"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2021.03.047","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson\u2019s disease patients: A randomized controlled study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2021.03.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}